, Volume 15, Issue 10, pp 2981-2982
Date: 14 Mar 2008

Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer—Promises and Reality

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

To the Editor

Dr. Folkman—a surgeon for years—proposed for the first time the idea that the dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for therapy.1

Now, four decades later, despite major advances in this research field, the clinical success of antiangiogenic therapy in solid cancers has been modest. No clinical implication has been occurred in the adjuvant setting, and contrasting results for metastatic setting are reported.2,3 Cancer is much more complicated than we have supposed. Cure for metastatic disease will probably remain elusive in this century. Even in the adjuvant setting, despite novel combinations with surgery, radiotherapy, and new systemic therapies, cure rates of patients with solid cancers will only be moderately improved in the near future.

Bevacizumab (Avastin)—a humanized monoclonal antibody directed against vascular endothelial growth factor A (VEGF-A)—is currently approved by the U.S. Food and Drug Administr ...